Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children’s Oncology Group
Engaging patients, families, and clinicians promotes care transitions between inpatient and outpatient settings and minimizes complications. Ongoing institutional commitment to monitor and capture emerging trends in blinatumomab administration can inform future optimal care practices.
Authors
- Holly R. Kubaney
- Shelby Smith (ORCID: https://orcid.org/0000-0002-2755-5108)
- Rachel E. Rau (ORCID: https://orcid.org/0000-0003-4096-6603)
- Kathleen Montgomery (ORCID: https://orcid.org/0000-0001-7662-0247)
- Olga Militano
- Sumit Gupta (ORCID: https://orcid.org/0000-0003-1334-3670)
- Sue Zupanec (ORCID: https://orcid.org/0000-0003-1755-7203)
- Katelyn Oranges
- Maki Okada (ORCID: https://orcid.org/0009-0005-3331-8191)
- Lauren Guidry
- Megan Elizabeth Wegter
Institutions
- Orange (Poland) (PL)
- State Administration of Foreign Experts Affairs (CN)
- Cleveland Community College (US)
- St. Elizabeth Healthcare (US)
- Sumgayit State University (AZ)
- Controlled Chemicals (United States) (US)
- Jupiter Medical Center (US)
- Roth and Rau (Germany) (DE)
- Joseph Sarwuan Tarka University Makurdi (NG)
- Hospital Central Militar (MX)
Publication Details
- Journal
- Clinical journal of oncology nursing
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1188/25.cjon.303-312
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00